NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high cholesterol (primary hypercholesterolaemia - heterozygous-familial and non-familial) and mixed dyslipidaemia.
08 February 2016
NICE – the National Institute for Health and Care Excellence – is consulting on potential new indicators for the NICE indicator menu. Indicators encourage health professionals to assess patients on a range of key health issues where diagnosis and treatment is supported by evidence-based guidelines. The aim is to tackle widespread public health challenges one patient at a time.
01 February 2016
NICE – the National Institute for Health and Care Excellence – is consulting on draft recommendations for the diagnosis and management of the blood cancer non-Hodgkin's lymphoma in adults and young people.
29 January 2016
NICE – the National Institute for Health and Care Excellence – has published its final recommendations on whether 6 different drug treatments should be routinely funded by the NHS.
27 January 2016
In final updated guidance published today NICE recommends a number of drugs called biological disease modifying drugs (DMARDs) as options for treating severei rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs. The guidance does not recommend their use for treating moderate active rheumatoid arthritis.
26 January 2016
NICE is asking for views on its plans to support using a device for treating enlarged prostate glands – benign prostatic hyperplasia – in a consultation opening today (Tuesday 26 January).
26 January 2016
0300 323 0142
(this number rings all our phones and is the best number to contact us on 9:00 – 17:30 Mon - Fri)
(out of office hours number)
Press releases are usually issued under embargo on the day before they are published on the website. If you are a journalist and would like to be added to our mailing list, please contact a member of the team.